Lakhasly

Absorption of levothyroxine Approximately 62-82% of levothyroxine is absorbed after oral administration.Early reports described elevated serum TSH levels in patients with coeliac sprue and inflammatory bowel disease despite thyroxine doses that had previously normalised serum levels.Patients with jejunoileal bypass surgery or other bowel resection have been reported to require higher doses of levothyroxine following surgery.2, 3, 4 Stone et al. noted reduced peak Food and dietary fibre Absorption of levothyroxine has been shown to be influenced both by the timing of food intake and by certain foods.Using the double-isotope method developed by Hays, the authors showed that absorption was significantly better in the fasting state Gastrointestinal disorders Both malabsorptive disorders and conditions that impair gastric acidity can affect the bioavailability of levothyroxine.

Absorption of levothyroxine
Approximately 62–82% of levothyroxine is absorbed after oral administration. This absorption occurs within the first 3 h of ingestion and is localised mainly in the jejunum and ileum.1 The absorption of levothyroxine is maximal when the stomach is empty, reflecting the importance of gastric acidity in this process. Patients with jejunoileal bypass surgery or other bowel resection have been reported to require higher doses of levothyroxine following surgery.2, 3, 4 Stone et al. noted reduced peak
Food and dietary fibre
Absorption of levothyroxine has been shown to be influenced both by the timing of food intake and by certain foods. This was first reported by Wenzel et al. in their study comprising 37 patients.13 Subjects ingested either 100 μg or 3 mg of levothyroxine under two settings: (1) fasting, or (2) immediately before the consumption of two buttered rolls and a boiled egg. Using the double-isotope method developed by Hays, the authors showed that absorption was significantly better in the fasting state
Gastrointestinal disorders
Both malabsorptive disorders and conditions that impair gastric acidity can affect the bioavailability of levothyroxine. Early reports described elevated serum TSH levels in patients with coeliac sprue and inflammatory bowel disease despite thyroxine doses that had previously normalised serum levels. These findings suggest that pre-existing malabsorption can reduce the bioavailability of levothyroxine. This association appears to be strongest with coeliac disease. More recently, a study has
Medications
Several commonly used oral medications have been shown to alter the bioavailability of levothyroxine, many of which interfere by forming an insoluble or non-absorbable complex with levothyroxine.